Axitinib is a targeted therapy drug used in the treatment of metastatic renal cell carcinoma (RCC). It works to block certain proteins, known as vascular endothelial growth factor receptors (VEGFRs), from growing and spreading. This allows for improved outcomes in patients with this form of cancer. However, like other treatments, there are risks and side effects associated with its use. In this article, we will discuss what you need to know about axitinib in order to make informed decisions about your treatment plan. We will explore how it works, the different types available, common side effects associated with use, and other important information that can help you feel confident in your choice of treatment.
Axitinib is a targeted cancer therapy that works by inhibiting the activity of tyrosine kinase enzymes. These enzymes are involved in the growth and spread of cancer cells. Axitinib is used to treat renal cell carcinoma (RCC), a type of kidney cancer. It is typically used after other treatments, such as surgery, have failed. Axitinib may also be used to treat other types of cancers, such as thyroid cancer or non-small cell lung cancer (NSCLC).
Axitinib belongs to a class of drugs known as kinase inhibitors. Kinase inhibitors work by blocking the activity of certain enzymes, which can help stop the growth and spread of cancer cells. Axitinib is a targeted therapy, which means it targets specific molecules that are involved in the growth and spread of cancer cells. Axitinib inhibits the activity of tyrosine kinase enzymes. These enzymes are found in healthy cells, but they are overactive in cancer cells. By inhibiting these enzymes, axitinib can help stop the growth and spread of cancer cells.
Axitinib works by inhibiting the vascular endothelial growth factor (VEGF) receptor. This protein is responsible for the growth and development of new blood vessels. When the VEGF receptor is inhibited, blood vessel growth is prevented, which in turn slows down the growth of cancerous tumors. Axitinib has been shown to be effective in treating several types of cancer, including renal cell carcinoma, gastrointestinal stromal tumor, and thyroid cancer.
The most common side effects of Axitinib are diarrhea, fatigue, high blood pressure, loss of appetite, and nausea. Less common side effects include bleeding, brain hemorrhage, heart attack, kidney failure, and liver damage. Some of the more rare side effects include hair loss, skin rash, and vision changes.
If you miss a dose of axitinib, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Axitinib is a powerful cancer-fighting drug that can be used to treat certain types of tumors. While the side effects and risks associated with its use must always be taken into account, it has been proven effective in many cases. With careful monitoring and guidance from your oncologist or hematologist, axitinib can be incorporated into an individualized treatment plan that helps you manage your disease while minimizing any potential adverse reactions.
1.
Finding a clue to the origin of treatment-resistant leukemia in kids
2.
Survivors of childhood brain cancer are more likely to be held back in school
3.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
4.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
5.
Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.
1.
Phosphate Vs. Phosphorus: What Is The Difference?
2.
Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development
3.
Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments
4.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
5.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Efficient Management of First line ALK-rearranged NSCLC - Part III
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation